Multisystemic Inflammatory Syndrome Post COVID-19 Infection in an Arab Female: A Case Report of a Rare Manifestation

M. Jhancy, Areen Yousef Al Tamakee, Hesham Mohamed Fayad
{"title":"Multisystemic Inflammatory Syndrome Post COVID-19 Infection in an Arab Female: A Case Report of a Rare Manifestation","authors":"M. Jhancy, Areen Yousef Al Tamakee, Hesham Mohamed Fayad","doi":"10.2174/04666230327122858","DOIUrl":null,"url":null,"abstract":"\n\nMultisystemic inflammatory syndrome is a rare but severe complication in children and adolescents infected with SARS-CoV-2.\n\n\n\nThis report describes a four-year-old Arab descent female presenting with a history of high-grade fever of 7 days duration with erythematous rash and family history of COVID infection suggestive of atypical Kawasaki disease, which turned out to be multisystemic inflammatory syndrome in a child (MIS-C) post COVID infection. Based on the available published evidence, the World Health Organization has provided a preliminary definition of MIS-C as “children and adolescents 0–19 years of age with fever > 3 days presenting with two of five clinical criteria, such as 1. skin rash or mucocutaneous inflammation or non-purulent conjunctivitis, 2. hypotensive shock, 3. signs of myocardial dysfunction, 4. coagulopathy, and 5. the acute gastrointestinal problem, elevated inflammatory markers, no evidence of other microbial infections, and evidence of COVID-19 (RT-PCR, antigen test or serology positive), or likely contact with patients with COVID-19”.\nSome criteria are similar, and others are different from Kawasaki disease and toxic shock syndrome, such as the presence of rash, conjunctivitis, mucocutaneous inflammation, and coronaries involvement are shared criteria between Kawasaki and MIS-C, whereas hypotensive shock and coagulopathy are shared criteria between MIS-C and toxic shock syndrome. The positive testing for COVID-19 in the absence of microbiological isolation confirms MIS-C.\n\n\n\nAmong the complications of COVID-19 infection, MIS-C is rare. Owing to the management differences among Kawasaki, toxic shock syndrome, and MIS-C, timely diagnosis of MIS-C saves the children from a poor outcome.\n","PeriodicalId":110816,"journal":{"name":"New Emirates Medical Journal","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"New Emirates Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/04666230327122858","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Multisystemic inflammatory syndrome is a rare but severe complication in children and adolescents infected with SARS-CoV-2. This report describes a four-year-old Arab descent female presenting with a history of high-grade fever of 7 days duration with erythematous rash and family history of COVID infection suggestive of atypical Kawasaki disease, which turned out to be multisystemic inflammatory syndrome in a child (MIS-C) post COVID infection. Based on the available published evidence, the World Health Organization has provided a preliminary definition of MIS-C as “children and adolescents 0–19 years of age with fever > 3 days presenting with two of five clinical criteria, such as 1. skin rash or mucocutaneous inflammation or non-purulent conjunctivitis, 2. hypotensive shock, 3. signs of myocardial dysfunction, 4. coagulopathy, and 5. the acute gastrointestinal problem, elevated inflammatory markers, no evidence of other microbial infections, and evidence of COVID-19 (RT-PCR, antigen test or serology positive), or likely contact with patients with COVID-19”. Some criteria are similar, and others are different from Kawasaki disease and toxic shock syndrome, such as the presence of rash, conjunctivitis, mucocutaneous inflammation, and coronaries involvement are shared criteria between Kawasaki and MIS-C, whereas hypotensive shock and coagulopathy are shared criteria between MIS-C and toxic shock syndrome. The positive testing for COVID-19 in the absence of microbiological isolation confirms MIS-C. Among the complications of COVID-19 infection, MIS-C is rare. Owing to the management differences among Kawasaki, toxic shock syndrome, and MIS-C, timely diagnosis of MIS-C saves the children from a poor outcome.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
阿拉伯女性COVID-19感染后多系统炎症综合征1例罕见表现
多系统炎症综合征是感染SARS-CoV-2的儿童和青少年中一种罕见但严重的并发症。本报告描述了一名四岁阿拉伯裔女性,其表现为持续7天的高热病史,并伴有红斑皮疹和COVID感染家族史,提示非典型川崎病,其在COVID感染后被证实为儿童多系统炎症综合征(misc)。根据现有已发表的证据,世界卫生组织对misc作出了初步定义,即“0-19岁的儿童和青少年,发热> 3天,符合5项临床标准中的2项,如1。2.皮疹或皮肤粘膜炎症或非化脓性结膜炎;低血压休克,3例。心肌功能障碍的迹象,4。4 .凝血功能障碍;急性胃肠道问题,炎症标志物升高,无其他微生物感染证据,COVID-19证据(RT-PCR、抗原检测或血清学阳性),或可能与COVID-19患者接触”。有些诊断标准与川崎病和中毒性休克综合征相似,有些则不同,如皮疹、结膜炎、皮肤粘膜炎症和冠状动脉受累是川崎病和中毒性休克综合征的共同诊断标准,而低血压休克和凝血功能障碍是中毒性休克综合征和川崎病的共同诊断标准。在没有微生物分离的情况下,COVID-19检测呈阳性,证实为misc。在COVID-19感染的并发症中,misc是罕见的。由于川崎、中毒性休克综合征和misc的治疗方法不同,及时诊断misc可以避免患儿预后不良。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.10
自引率
0.00%
发文量
0
期刊最新文献
Predictors of Mortality Following Mitral Valve Replacement: A Systematic Review Field Study on the Assessment of Antimalarial Drug Quality Using Minilab Kit in India Crossed Aphasia without Hemiparesis in a Dextral: A Case Report “A Comprehensive Review of Anaemia Associated with Hypothyroidism” Evaluation of Urinary Interleukin-18 Changes in Patients Treated with Vancomycin
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1